A Phase 2 Study With IPI-926 in Patients With Myelofibrosis
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of IPI-926 in patients with
myelofibrosis (MF) (primary myelofibrosis [PMF], post-polycythemia vera myelofibrosis
[post-PV MF], or post-essential thrombocythemia myelofibrosis [post-ET MF]).